Vanguard Personalized Indexing Management LLC Purchases 2,429 Shares of Natera, Inc. $NTRA

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Natera, Inc. by 19.2%, acquiring an additional 2,429 shares, bringing its total holdings to 15,058 shares valued at approximately $2.54 million.
• Insider trading reveals that Director Rowan E. Chapman sold 2,750 shares, while CEO Steven Leonard Chapman sold 14,083 shares, indicating a significant 8.38% decrease in the CEO's ownership.
• Natera reported a loss of $0.74 EPS for the most recent quarter despite a revenue increase of 32.2% year-over-year, missing the analyst consensus estimate.

Vanguard Personalized Indexing Management LLC increased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 19.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,058 shares of the medical research company's stock after purchasing an additional 2,429 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Natera were worth $2,544,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Bank of Jackson Hole Trust purchased a new position in shares of Natera during the 1st quarter valued at approximately $29,000. Rakuten Securities Inc. increased its holdings in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC purchased a new position in shares of Natera during the 1st quarter valued at approximately $32,000. TCTC Holdings LLC increased its holdings in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00. Following the completion of the sale, the chief executive officer owned 154,072 shares of the company's stock, valued at $24,651,520. This trade represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is currently owned by company insiders.

Natera Trading Up 3.8%

NTRA stock opened at $179.42 on Thursday. The company has a market capitalization of $24.63 billion, a P/E ratio of -93.94 and a beta of 1.74. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00. The business has a 50 day simple moving average of $166.81 and a 200-day simple moving average of $157.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same quarter in the previous year, the company posted ($0.30) EPS. The company's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on NTRA. Wells Fargo & Company began coverage on shares of Natera in a report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price target for the company. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $194.06.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.